Study Review - Depot Buprenorphine for Opioid Substitution Therapy in Custodial Settings

As part of our ongoing effort to bring you reports of interesting new studies, we have added a study that assessed the safety and tolerability of slow-release depot buprenorphine when used for opioid substitution therapy in correctional centres in New South Wales.

Independent expert commentary is provided by Professor Michael Farrell, Director of the National Drug and Alcohol Research Centre (NDARC) at the University of New South Wales, Sydney NSW and Faculty Theme Lead of Mental Health, Neuroscience, Ageing and Addictions, UNSW Medicine.

Please login below to download this issue (PDF)